SKAN Group AG (SKAN) AI Stock Analysis

• Market Cap: CHF953.30M
• Dividend Yield: 0.77%
• Average Volume (3M): 22.50K
• Price to Earnings (P/E): 72.9
• Beta (1Y): 0.83
• Revenue Growth: -3.45%
• EPS Growth: -49.82%
• Country: CH
• Employees: 1,377
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.12
• Shares Outstanding: 22,483,524
• 10 Day Avg. Volume: 19,367
• 30 Day Avg. Volume: 22,504
• PEG Ratio: -1.25
• Price to Book (P/B): 10.37
• Price to Sales (P/S): 3.56
• P/FCF Ratio: 56.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF62.50
• Price Target Upside: 14.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 1.74
• Revenue Forecast (FY): CHF405.40M

• Rating: 52 Neutral
• Price Target: CHF43.00 ▼(-21.10% Downside)
• Action: Reiterated Date: 03/26/26
• Date: Action: Reiterated 03/26/26

The score is driven primarily by mixed financial performance: strong top-line growth and improved 2025 cash flow are offset by a sharp increase in leverage and weaker 2025 profitability. Technicals are a significant headwind given the clear downtrend and negative momentum indicators. Valuation also weighs on the score due to a high P/E and a modest dividend yield.

Positive Factors

Top-line growth & high gross margins

A strong revenue rebound and persistently high gross margins indicate durable demand for SKAN's aseptic solutions and a structurally profitable product mix. High gross margins support reinvestment in R&D and service capabilities, and provide a cushion against cyclical project timing over the medium term.

Negative Factors

Sharp rise in leverage

A material increase in debt-to-equity sharply reduces balance sheet flexibility and heightens refinancing and interest-rate risk. If elevated leverage persists while margins are volatile, the company faces constrained ability to invest, withstand project timing shocks, or pursue bolt-on opportunities over the medium term.

SKAN Group AG Business Overview & Revenue Model

Company Description

SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions (E&S) and Servic...

Read more

SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions (E&S) and Servic...

How the Company Makes Money

SKAN makes money primarily by selling and delivering aseptic processing and containment solutions to pharmaceutical and biotech manufacturers, and by providing associated services over the installed base of equipment. Key revenue streams include:...

Read more

SKAN makes money primarily by selling and delivering aseptic processing and containment solutions to pharmaceutical and biotech manufacturers, and by providing associated services over the installed base of equipment. Key revenue streams include:...

SKAN Group AG Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	333.33M	361.30M	320.02M	276.95M	234.26M
Gross Profit	230.31M	265.88M	234.08M	200.50M	170.11M
EBITDA	36.03M	59.68M	50.14M	40.15M	32.38M
Net Income	16.27M	38.80M	26.31M	18.99M	10.62M
Balance Sheet
Total Assets	481.08M	384.49M	373.45M	388.35M	331.92M
Cash, Cash Equivalents and Short-Term Investments	94.08M	61.71M	85.12M	135.98M	131.54M
Total Debt	131.47M	10.61M	6.49M	16.88M	15.27M
Total Liabilities	347.81M	181.92M	197.09M	222.76M	157.92M
Stockholders Equity	114.45M	196.16M	169.23M	157.30M	159.75M
Cash Flow
Free Cash Flow	21.01M	-7.09M	-26.60M	32.62M	-32.29M
Operating Cash Flow	64.11M	46.70M	8.70M	61.48M	10.32M
Investing Cash Flow	-130.91M	-69.06M	-17.35M	-76.42M	-11.02M
Financing Cash Flow	108.99M	-9.35M	-15.80M	-4.85M	67.48M

SKAN Group AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SKAN, the sentiment is Negative. The current price of 54.5 is above the 20-day moving average (MA) of 45.39, above the 50-day MA of 50.86, and below the 200-day MA of 57.02, indicating a bearish trend. The MACD of -2.47 indicates Positive momentum. The RSI at 35.13 is Neutral, neither overbought nor oversold. The STOCH value of 60.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SKAN.

SKAN Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SFSN	73 Outperform	CHF4.59B	19.27	―	1.85%	-0.71%	-6.12%
YPSN	70 Outperform	CHF3.81B	7.66	27.15%	0.67%	27.63%	160.67%
STMN	66 Neutral	CHF13.31B	41.72	―	1.02%	4.49%	45.08%
TECN	55 Neutral	CHF1.74B	-14.70	4.57%	2.31%	-9.34%	-37.50%
SKAN	52 Neutral	CHF953.30M	72.95	―	0.77%	-3.45%	-49.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COTN	50 Neutral	CHF1.98B	143.14	―	0.68%	27.24%	122.39%

SKAN Group AG Corporate Events